Reduce GST on Medicines, Diagnostic kits & Medical instruments from 12 to 5%: Nathealth study

The goods and services tax (GST) rate on certain sector-specific items including medicines, diagnostic kits and medical instruments should be brought down from 12 per cent to five per cent in order to address the issue of embedded tax in the healthcare services sector, says a latest study.

A White Paper by consultancy major EY along with Healthcare Federation of India (Nathealth), on the study of embedded taxes in the healthcare sector in the country, states that the GST exemption on healthcare services at a time when the inputs used by the healthcare firms are taxed at 12-18 per cent is resulting in embedded taxes in the range of 5.5-6 per cent of the total revenue of healthcare units. The study was conducted among hospitals and testing labs of various sizes, among others.

The GST has been exempted for healthcare services sector, including clinical establishments such as hospitals, nursing homes and clinics or authorised medical practitioner or paramedics, on the assumption that a majority of healthcare establishments would not come under the GST regime and would be relieved of fulfilling a lot of GST related procedures like ‘Registration’ and ‘filing of Returns’.

“Unfortunately, due to this, the most promising feature of the GST of facilitating smooth flow of input tax credit got restricted as most of the inputs procured by the healthcare establishments including medical equipment’s, consumables, labour and maintenance of medical equipment’s, rental services, housekeeping services, etc bore the GST burden, but these taxes could not be set off against the output tax liability because the output healthcare services were exempt from GST,” said the study.

The blocked credit, which remains unutilised in the value chain becomes a cost and gets passed on to the end user raising the cost for healthcare services and thereby diluting the government objective of making India an affordable healthcare destination.

For hospitals, the embedded taxes on an average account for nearly 6 per cent of their total expenses in a year, though for the last three years, this has stayed at an average of 5.7 per cent.

Over the past three years, the average GST rate faced by hospitals on procuring their inputs has been about 12 per cent, and the out of the expenditure, almost 40.6 per cent of their total expenditure in 2018-19 were into GST bearing inputs, ranging from pharmacy consumption including both life saving and non-life saving medicines, food and beverages, printing and stationary, instruments, machinery to several input services, manpower supply services, maintenance and repair services, among others.

The study shows that almost 47 per cent of the GST bearing expenses for a hospital are medicines other than life saving drugs, and they are charged with 12 per cent GST. The contractual labour expenses is the second highest contribution in the GST bearing expense, at 28 per cent of the total expenses, and is charged at 18 per cent GST rate.

Instruments and appliances used in medical, surgical, dental or veterinary sciences contributes to 12 per cent of the GST bearing expenses for hospitals, and are charged at 12 per cent GST.

For testing labs, the embedded taxes on an average account for nearly 5.2 per cent of their total expenses in a year, while across the three years the rate stayed at an average of 5.8 per cent. This was less than five per cent for the year 2020-21 because of the higher volume of demand for C-19-related testing services.

Over the past three years, the average GST rate faced by labs on procuring their inputs has been about 12 per cent. Consumables and reagents contribute to around 44-75 per cent of the lab’s total GST bearing expenses, which are taxed at five, 12 and 18 per cent.

For hospitals, the embedded taxes rate has increased from 4.3 per cent in 2016-17 to 5.7 per cent in the GST period, as per the data provided by the healthcare providers. Meanwhile, for testing labs, the embedded taxes rate has increased from 3.8 per cent to 5.8 per cent, during the same period. Thus, the healthcare services sector provides a unique case wherein the GST regime has not augured well for the service providers.

“In this context, a GST rate rationalisation exercise is much needed in the sector to overcome the embedded taxes problem and provide for opportunities to healthcare service providers to invest in high quality inputs to provide high quality output to end-consumers,” said the study.

“As the entire exercise of GST rate structure rationalisation is under examination by a commission under GST council, our request is that at least a few important items which account for a significant proportion of embedded taxes could be brought to a merit rate, providing some relief to the healthcare services segment, and at least neutralise the increase of 1.5 per cent post C-19 (in GST regime),” it added.

It has requested the government to reduce the GST rate of all diagnostic kits and reagents, medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, medical, surgical, dental or veterinary furniture, instruments and appliances used in medical, surgical, dental or veterinary sciences, and others from the current 12 per cent to 5 per cent.

Related Posts

  • Pharma
  • July 26, 2024
  • 128 views
US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

Maryland: The US Food and Drug Administration (FDA) has warned Brassica Pharma for numerous good manufacturing practice (GMP) violations, including multiple instances of employees falsifying sterility and environmental monitoring data and…

  • Pharma
  • July 26, 2024
  • 125 views
Indian National Charged With Selling Counterfeit Cancer Drugs

HOUSTON: A federal grand jury has returned an indictment charging an Indian national with selling and shipping tens of thousands of dollars in counterfeit oncology pharmaceuticals into the United States,…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

Indian National Charged With Selling Counterfeit Cancer Drugs

Indian National Charged With Selling Counterfeit Cancer Drugs

ICMR Releases 32 New Treatment Standards For Treating Common And Serious Diseases

ICMR Releases 32 New Treatment Standards For Treating Common And Serious Diseases

BIS Sanctioned 82 Medical Device Projects To Develop Standards

BIS Sanctioned 82 Medical Device Projects To Develop Standards

Anti-Narcotics Task Force Will Be Formed Soon In Rajasthan: HM

Anti-Narcotics Task Force Will Be Formed Soon In Rajasthan: HM

‘Sunrise’ MedTech Industry in India & ‘Clouds’ strangling it, Brainstormed in PHD

‘Sunrise’ MedTech Industry in India & ‘Clouds’ strangling it, Brainstormed in PHD